(NTR) Nutrien - Overview
Stock: Fertilizer, Potash, Nitrogen, Phosphate, Crop Inputs
| Risk 5d forecast | |
|---|---|
| Volatility | 33.7% |
| Relative Tail Risk | -4.69% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.84 |
| Alpha | 59.66 |
| Character TTM | |
|---|---|
| Beta | 0.370 |
| Beta Downside | 0.694 |
| Drawdowns 3y | |
|---|---|
| Max DD | 37.64% |
| CAGR/Max DD | 0.23 |
EPS (Earnings per Share)
Revenue
Description: NTR Nutrien March 02, 2026
Nutrien Ltd. (NYSE: NTR) is a vertically integrated agribusiness that supplies crop inputs and services through four operating segments: Nutrien Ag Solutions, Potash, Nitrogen, and Phosphate. The Ag Solutions arm offers a full suite of nutrients, crop-protection chemicals, seeds, and related services such as soil testing, precision-ag technology, and financing. The Potash segment markets granular and standard potash fertilizers, while the Nitrogen segment produces ammonia, urea, and “environmentally smart” nitrogen solutions. The Phosphate division delivers solid and liquid phosphate fertilizers along with industrial and feed-grade products.
In its most recent fiscal year (FY 2025), Nutrien reported revenue of $33.9 billion, a 7 % increase year-over-year, driven largely by higher commodity prices and strong demand for nitrogen-based fertilizers. EBITDA margin expanded to 15.2 % (up from 13.8 % in FY 2024), and the company generated $2.4 billion of free cash flow, supporting a $1.0 billion share-repurchase program. Spot potash prices have risen to roughly $470 per metric ton, while nitrogen fertilizer prices are up about 12 % YoY, reflecting tight supply and robust global grain planting intentions.
Key macro drivers include rising global food demand projected to grow 1.5 % annually through 2030, tighter fertilizer supply chains, and increasing adoption of precision-ag technologies that boost crop-yield efficiency. These trends position Nutrien to benefit from both volume growth and higher pricing power across its product lines.
For a deeper dive into Nutrien’s valuation and how it fits within the broader fertilizer sector, consider exploring the analysis on ValueRay.
Headlines to watch out for
- Global fertilizer prices directly impact Nutriens revenue and profitability
- Agricultural commodity prices influence farmer demand for inputs
- Energy costs significantly affect fertilizer production expenses
- Regulatory changes in agriculture impact product approvals and sales
- Weather patterns and growing conditions drive crop input demand
Piotroski VR‑10 (Strict, 0-10) 7.0
| Net Income: 2.27b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.04 > 0.02 and ΔFCF/TA 1.06 > 1.0 |
| NWC/Revenue: 13.76% < 20% (prev 6.73%; Δ 7.03% < -1%) |
| CFO/TA 0.08 > 3% & CFO 4.05b > Net Income 2.27b |
| Net Debt (12.23b) to EBITDA (6.11b): 2.00 < 3 |
| Current Ratio: 1.34 > 1.5 & < 3 |
| Outstanding Shares: last quarter (483.2m) vs 12m ago -1.97% < -2% |
| Gross Margin: 31.06% > 18% (prev 0.29%; Δ 3.08k% > 0.5%) |
| Asset Turnover: 51.71% > 50% (prev 50.10%; Δ 1.61% > 0%) |
| Interest Coverage Ratio: 5.44 > 6 (EBITDA TTM 6.11b / Interest Expense TTM 687.9m) |
Altman Z'' 2.69
| A: 0.07 (Total Current Assets 14.72b - Total Current Liabilities 11.02b) / Total Assets 52.21b |
| B: 0.23 (Retained Earnings 12.05b / Total Assets 52.21b) |
| C: 0.07 (EBIT TTM 3.74b / Avg Total Assets 52.02b) |
| D: 0.94 (Book Value of Equity 25.22b / Total Liabilities 26.89b) |
| Altman-Z'' Score: 2.69 = A |
Beneish M -2.98
| DSRI: 1.18 (Receivables 5.66b/4.63b, Revenue 26.90b/25.97b) |
| GMI: 0.93 (GM 31.06% / 28.99%) |
| AQI: 0.95 (AQ_t 0.28 / AQ_t-1 0.30) |
| SGI: 1.04 (Revenue 26.90b / 25.97b) |
| TATA: -0.03 (NI 2.27b - CFO 4.05b) / TA 52.21b) |
| Beneish M-Score: -2.98 (Cap -4..+1) = A |
What is the price of NTR shares?
Over the past week, the price has changed by +9.29%, over one month by +18.59%, over three months by +35.13% and over the past year by +65.09%.
Is NTR a buy, sell or hold?
- StrongBuy: 10
- Buy: 5
- Hold: 8
- Sell: 1
- StrongSell: 1
What are the forecasts/targets for the NTR price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 74.8 | -9.7% |
| Analysts Target Price | 74.8 | -9.7% |
NTR Fundamental Data Overview March 14, 2026
P/E Forward = 17.0648
P/S = 1.5443
P/B = 1.5949
P/EG = 0.5792
Revenue TTM = 26.90b USD
EBIT TTM = 3.74b USD
EBITDA TTM = 6.11b USD
Long Term Debt = 9.35b USD (from longTermDebt, last quarter)
Short Term Debt = 1.73b USD (from shortTermDebt, last quarter)
Debt = 12.93b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 12.23b USD (from netDebt column, last quarter)
Enterprise Value = 52.31b USD (40.07b + Debt 12.93b - CCE 699.7m)
Interest Coverage Ratio = 5.44 (Ebit TTM 3.74b / Interest Expense TTM 687.9m)
EV/FCF = 26.38x (Enterprise Value 52.31b / FCF TTM 1.98b)
FCF Yield = 3.79% (FCF TTM 1.98b / Enterprise Value 52.31b)
FCF Margin = 7.37% (FCF TTM 1.98b / Revenue TTM 26.90b)
Net Margin = 8.44% (Net Income TTM 2.27b / Revenue TTM 26.90b)
Gross Margin = 31.06% ((Revenue TTM 26.90b - Cost of Revenue TTM 18.55b) / Revenue TTM)
Gross Margin QoQ = 35.36% (prev 32.70%)
Tobins Q-Ratio = 1.00 (Enterprise Value 52.31b / Total Assets 52.21b)
Interest Expense / Debt = 1.44% (Interest Expense 185.8m / Debt 12.93b)
Taxrate = 21.41% (160.4m / 749.3m)
NOPAT = 2.94b (EBIT 3.74b * (1 - 21.41%))
Current Ratio = 1.34 (Total Current Assets 14.72b / Total Current Liabilities 11.02b)
Debt / Equity = 0.51 (Debt 12.93b / totalStockholderEquity, last quarter 25.28b)
Debt / EBITDA = 2.00 (Net Debt 12.23b / EBITDA 6.11b)
Debt / FCF = 6.17 (Net Debt 12.23b / FCF TTM 1.98b)
Total Stockholder Equity = 24.88b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.36% (Net Income 2.27b / Total Assets 52.21b)
RoE = 9.13% (Net Income TTM 2.27b / Total Stockholder Equity 24.88b)
RoCE = 10.93% (EBIT 3.74b / Capital Employed (Equity 24.88b + L.T.Debt 9.35b))
RoIC = 7.90% (NOPAT 2.94b / Invested Capital 37.20b)
WACC = 5.78% (E(40.07b)/V(53.00b) * Re(7.28%) + D(12.93b)/V(53.00b) * Rd(1.44%) * (1-Tc(0.21)))
Discount Rate = 7.28% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -1.18%
[DCF] Terminal Value 81.72% ; FCFF base≈1.76b ; Y1≈1.22b ; Y5≈622.3m
[DCF] Fair Price = 15.33 (EV 19.61b - Net Debt 12.23b = Equity 7.38b / Shares 481.1m; r=5.90% [WACC]; 5y FCF grow -35.86% → 2.90% )
EPS Correlation: -50.71 | EPS CAGR: -26.99% | SUE: -0.55 | # QB: 0
Revenue Correlation: -44.53 | Revenue CAGR: -8.79% | SUE: 2.37 | # QB: 1
EPS next Quarter (2026-06-30): EPS=2.70 | Chg7d=-0.003 | Chg30d=+0.076 | Revisions Net=+2 | Analysts=15
EPS current Year (2026-12-31): EPS=4.86 | Chg7d=+0.029 | Chg30d=+0.110 | Revisions Net=+4 | Growth EPS=+6.5% | Growth Revenue=+2.1%
EPS next Year (2027-12-31): EPS=4.79 | Chg7d=+0.109 | Chg30d=+0.209 | Revisions Net=+3 | Growth EPS=-1.4% | Growth Revenue=+0.4%
[Analyst] Revisions Ratio: +0.25 (5 Up / 3 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 2.3% (Discount Rate 7.9% - Earnings Yield 5.6%)
[Growth] Growth Spread = -2.2% (Analyst 0.1% - Implied 2.3%)